v3.25.1
BUSINESS COMBINATION - Narrative (Details)
3 Months Ended 7 Months Ended 12 Months Ended
Sep. 16, 2024
USD ($)
contingentValueRight
$ / shares
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Business Acquisition [Line Items]          
Selling, general and administrative expenses   $ 76,528,000 $ 48,021,000    
Research and development expense   10,564,000 10,511,000    
Alimera Sciences, Inc          
Business Acquisition [Line Items]          
Common Stock, par value (in dollars per share) | $ / shares $ 0.01        
Cash consideration per share (in dollars per share) | $ / shares $ 5.50        
Business combination, number of contingent value rights to be received | contingentValueRight 1        
Repayment of Alimera Debt $ 78,540,000        
Payment of Alimera transaction costs 20,172,000        
Payment of settlement of acquiree's equity awards 19,300,000        
Cash paid at closing for settlement of equity awards 1,300,000        
Cash settlement for pre-acquisition equity awards 9,535,000        
Selling, general and administrative expenses         $ 8,800,000
Research and development expense         $ 1,000,000.0
Fair value of CVRs 8,322,000        
Business combination, contingent value rights $ 8,700,000        
Goodwill decrease on adjustment   200,000   $ 235,000  
Payment of Alimera transaction costs   900,000 $ 0    
Alimera Sciences, Inc | Contingent Value Right          
Business Acquisition [Line Items]          
Selling, general and administrative expenses   $ 400,000